Payment overview · 2025
General Payments
$261.79
3 reported records · 3 companies
Healthcare provider profile · identity verified
Jignesh R Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ST AUGUSTINE, FL · NPI 1487693636
Verified facts
What the public records show
CMS Open Payments records show Jignesh R Patel, MD received $261.79 in general payments during 2025 across 3 reported records.
Amgen Inc. accounted for 47.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $123.97 | 47.4% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $120.87 | 46.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.95 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $261.79 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $123.97 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $120.87 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 134 |
| Eliquis | Apixaban | 470 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 91 |
| Lisinopril | Lisinopril | 342 | 92 |
| Gabapentin | Gabapentin | 325 | 63 |
| Furosemide | Furosemide | 317 | 72 |
| Potassium Chloride | Potassium Chloride | 294 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 228 | 37 |
| Losartan Potassium | Losartan Potassium | 222 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 44 |
| Metformin Hcl | Metformin Hcl | 189 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 50 |
| Alprazolam | Alprazolam | 168 | 30 |
| Simvastatin | Simvastatin | 166 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 47 |
| Omeprazole | Omeprazole | 138 | 54 |
| Carvedilol | Carvedilol | 134 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 133 | 24 |
| Trazodone Hcl | Trazodone Hcl | 129 | 35 |
| Finasteride | Finasteride | 115 | 24 |
| Prednisone | Prednisone | 115 | 68 |
| Donepezil Hcl | Donepezil Hcl | 105 | 19 |
| Meloxicam | Meloxicam | 103 | 32 |
| Sertraline Hcl | Sertraline Hcl | 99 | 32 |
| Divalproex Sodium | Divalproex Sodium | 96 | 18 |
| Myrbetriq | Mirabegron | 91 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 91 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 30 |
| Atenolol | Atenolol | 83 | 18 |
| Cefdinir | Cefdinir | 83 | 57 |
| Montelukast Sodium | Montelukast Sodium | 83 | 26 |
| Mirtazapine | Mirtazapine | 81 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 39 |
| Amiodarone Hcl | Amiodarone Hcl | 76 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | 14 |
| Baclofen | Baclofen | 71 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 19 |
| Lorazepam | Lorazepam | 70 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 15 |
| Memantine Hcl | Memantine Hcl | 68 | 15 |
| Levetiracetam | Levetiracetam | 67 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 38 |
| Allopurinol | Allopurinol | 61 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 26 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Famotidine | Famotidine | 58 | 15 |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Glimepiride | Glimepiride | 57 | 16 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 56 | suppressed |
| Jardiance | Empagliflozin | 55 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Nystatin | Nystatin | 51 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 15 |
| Bumetanide | Bumetanide | 48 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Latanoprost | Latanoprost | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Metronidazole | Metronidazole | 39 | 21 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 38 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 26 |
| Insulin Aspart Flexpen | Insulin Aspart | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 20 |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Zonisamide | Zonisamide | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Micafungin | Micafungin Sodium | 28 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Ramipril | Ramipril | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sotalol Af | Sotalol Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Cefepime | Cefepime In Iso-Osm Dextrose | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Glatopa | Glatiramer Acetate | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | 12 |
| Glatiramer Acetate | Glatiramer Acetate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Daptomycin-0.9% Nacl | Daptomycin In 0.9 % Sod Chlor | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $261.79 · 3 records | Amgen Inc. | BREZTRI, KRYSTEXXA, TREMFYA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error